

Shortages of GLP-1 receptor agonists


Mitigation measures - Belgium

Multistakeholder workshop

01.07.2024

Sybille SCHOTTE


Timeline




07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to make exports subject to prior authorisation
07-12.2023	Other GLP 1-analogues reported unavailable
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing the conditions for the prescription and delivery



Mitigation measures - Belgium



07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to make exports subject to prior authorisation
07-12.2023	Other GLP 1-analogues reported unavailable
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing the conditions for the prescription and delivery




First notification of shortage:

- Start date shortage: 04.07.2022
- Periods of limited availability alternating with periods of complete stockout
- Mitigation measure: adaptation of the treatment
 - ➡ Other GLP1-analogues can be used



Mitigation measures - Belgium




07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to make exports subject to prior authorisation
07-12.2023	Other GLP 1-analogues reported as available
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing rules for importation and delivery

Recommendations for physicians and (hospital) pharmacists


- Priority should be given to the **authorised** indication
- Off-label use should be limited. Especially for use in the treatment of obesity where there is a body mass index (BMI) below 30 kg/m² or below 27 kg/m² in combination with at least one weight-related comorbidity
- When necessary, other GLP1-analogues can be used to treat adult patients with type 2 diabetes mellitus
- For the treatment of obesity, another medicinal product (authorised for this indication) can be used



Mitigation measures - Belgium



07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to make exports subject to prior authorisation
07-12.2023	Other GLP 1-analogues reported unavailable
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing the conditions for the prescription and delivery



Export of the medicinal products intended for the Belgian market subject to **prior authorisation**

No export ban!



Mitigation measures - Belgium



07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to make exports subject to prior authorisation
07-12.2023	Other GLP 1-analogues reported unavailable
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing the conditions for the prescription and delivery



Recommendations for physicians and (hospital) pharmacists

- Priority should be given to the **authorised** indication
- GLP1-analogues can also be prescribed for the **treatment of obesity**:
 - Body mass index (BMI) above **35 kg/m²** or above **30 kg/m²** in combination with at least one weight-related comorbidity
 - The initial prescription should be issued by an endocrinologist
 - Patients who met the above criteria at the start of their treatment should be able to continue their treatment as planned
 - Patients who did not meet the above criteria at the start of their treatment should gradually reduce or discontinue their GLP-1 analogue-based therapy in consultation with their general practitioner




Mitigation measures - Belgium

For which patients can these medicinal products be prescribed or delivered?

- ✓ Type 2 diabetes patients
- ✓ Patients with obesity with a BMI of $\geq 35\text{kg/m}^2$ *
- ✓ Patients with obesity with a BMI of $\geq 30\text{kg/m}^2$ in combination with at least one weightrelated comorbidity*
- ✓ Patients that are currently being treated with a GLP-1 analogue for the indication obesity who were eligible at the start of their treatment
- ✓ Patients receiving these medicinal products in the context of a clinical trial

*First prescription has to be written by an endocrinologist as part of a multidisciplinary approach.



A vertical timeline on the left side of the slide, indicated by a large blue downward arrow. It lists key events from July 2022 to November 2023. A pink arrow points from the 11.2023 entry to the list of patient criteria.

07.2022	First shortage
09.2022	Task Force issued recommendations
02.2023	Publication of Royal Decree to manage shortages
07-12.2023	Other GLP 1-analogues reported unavailability
10.2023	Task Force issued new (stricter) recommendations
11.2023	Publication of Royal Decree establishing the conditions for the prescription and delivery



Contact

Federal Agency for Medicines and Health Products – FAMHP

Avenue Galilée - Galileelaan 5/03
1210 BRUSSELS


tel. + 32 2 528 40 00

fax + 32 2 528 40 01

e-mail welcome@fagg-afmps.be

www.famhp.be

Follow the FAMHP on Facebook, Twitter and LinkedIn



A large, stylized graphic of a human eye in the background. The eye is composed of a light blue iris with a white pupil, and a grey, semi-transparent eyelid at the top. The entire graphic is centered on the page.

Your medicines and health products, our concern